{"task_id": "75699e80e8a14108", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 233/464)", "text": "3%. After detection of polyp,\n222\nCancer Screening\n\n--- Page 244 ---\nCOLON CANCER SCREENING (CONT\u2019D)\npatient would need to undergo optical colonoscopy\n(ideally on standby) for resection. Risk of radiation\nexposure\nFECAL OCCULT TEST (FOB)\ndetects peroxidase in\nblood. Rehydrated stool samples have been shown to\nreduce colorectal cancer mortality by 33% after 13\nyears if done annually and 21% after 18 years if done\nbiennially; non rehydrated stool samples have been\nshown to reduce colorectal cancer mortality by 18%\nafter 18 years if done biennially. Negative test in\n90 98% of cases (15 50% negative even with cancer)\n! repeat in 1 2 years; positive in 2 10% ! proceed\nto colonoscopy\nFECAL IMMUNOCHEMICAL TEST (FIT)\ndetects\nhuman globin. More specific and less sensitive than\nFOB\nSTOOL DNA TEST (sDNA)\nneed to provide entire\nstool sample. Insufficient evidence to support benefit\nOVERALL APPROACH\n\u0002\nAVERAGE RISK\nstart screening at age 50 with one\nof colonoscopy every 10 years, flexible sigmoido\nscopy every 5 years, FOB or FIT every 1 2 years, or\ndouble contrast barium enema every 5 years.\nBoth FOB and FIT detect primarily cancer, while\nthe rest detect mostly polyps (i.e. earlier stage\nand thus preferred). Insufficient data to recom\nmend routine CT colonoscopy or stool DNA\ntesting\n\u0002\nPOLYPS ON COLONOSCOPY\n1 2 tubular adenomas\n! colonoscopy in 5 years; >2 adenomas !\ncolonoscopy in 3 years; incomplete exam, numer\nous polyps, advanced adenoma, large sessile ade\nnoma ! repeat colonoscopy based on clinical\njudgment\n\u0002\nPOSITIVE FAMILY HISTORY\none first degree rela\ntive with cancer or adenomatous polyp at age\n<60 or two or more first degree relatives\nwith cancer or adenomatous polyp at any age\n! colonoscopy every 5 years beginning at 40\nor 10 years earlier than youngest index case\n(whichever first)\n\u0002\nHNPCC, FAP, OR ATTENUATED ADENOMATOUS POLYPO-\nSIS COLI (AAPC)\ngenetic counseling and special\nscreening. For HNPCC, colonoscopy every 1 2\nyears starting at 20 25 or 10 years earlier than\nyoungest index case in family (whichever first);\nfor FAP, colonoscopy annually beginning at\n10 12 years of age. For AAPC, colonoscopy\nannually beginning at 16 18 years of age\n\u0002 IBD (ulcerative colitis or Crohn\u2019s disease)\nstaging\ncolonoscopy 8 10 years after diagnosis; screening\ninterval should decrease with increasing duration\nof disease (variable). Annual colonoscopy for any\npatient with PSC\nBREAST CANCER SCREENING\nBREAST SELF EXAMINATION (BSE)\nno survival\nbenefit demonstrated on its own\nCLINICAL BREAST EXAMINATION (CSE)\nusually\ncombined with mammography in studies\nMAMMOGRAPHY\nsensitivity 16 40%. Meta analy\nsis showed 20 30% relative risk reduction (RRR) in\nbreast cancer mortality for women 50 69, 17% reduc\ntion for women 40 49, and inconclusive for women\naged 70 74\nBREAST MRI\nsensitivity 77 100% for breast cancer\nbut not very specific and less sensitive than mammo\ngraphy in detecting DCIS. Studies only in high risk\nwomen. No survival benefit demonstrated\nBREAST U/S\nmay represent an alternative in\nwomen with dense breasts and increased risk of\nbreast cancer who cannot tolerate MRI. No survival\nbenefit demonstrated\nOVERALL\nmammogram should be done every 1 2\nyears for women aged 40 or greater for as long as\nwomen is in good health, with CBE annually and BSE\nq6months. Breast MRI should be considered for\npatients at high risk of developing breast cancer\n(e.g. BRCA carriers, Li Fraumeni, previous chest\nirradiation)\nOVARIAN CANCER SCREENING\nCA125\nelevated in 80% of women with advanced\novarian cancer, <50% of stage I ovarian cancer, and\n1 2% of normal population. Low specificity\nTRANSVAGINAL U/S\nsensitivity 85% with PPV of\n27% for women over age 50 at average risk and\nthose over age 25 with family history of ovarian\ncancer\nOVERALL\nroutine screening for average risk indivi\nduals not recommended. For those at high risk\n(family history, BRCA mutation), the decision should\nbe individualized and may consist of transvaginal U/S\nand CA 125 every 6 months starting at age 35 or 5 10\nyears earlier than the youngest age at diagnosis in\nthe family\nCERVICAL CANCER SCREENING\nPAP SMEAR\n50 60% reduction in mortality if done\nevery 1 3 years in women aged 18 and greater.\nSensitivity and specificity for CIN2 and CIN3 are 55\nand 97%, respectively\nBETHESDA SYSTEM OF REPORTING CERVICAL\nCYTOLOGIC DIAGNOSIS\n\u0002\nSQUAMOUS CELL\natypical squamous cells of unde\ntermined significance (ASC US); atypical squamous\ncells cannot exclude HSIL (ASC H)\n\u0002\nLOW-GRADE\nSQUAMOUS\nINTRAEPITHELIAL\nLESION\n(LSIL)\nencompassing human papillomavirus, mild\ndysplasia, cervical intraepithelial neoplasia (CIN) 1\nCancer Screening\n223", "text_length": 4613, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 233/464)", "type": "chunk", "chunk_index": 232, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.567508", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.568232", "status": "complete", "chunks_added": 3}